Paulo Hoff

Paulo Hoff

Research

Dr. Hoff’s research line includes the development of new therapies for the treatment of gastrointestinal tumors. He participated in the development of 2 drugs: CAPECITABINE and TAS-102.
Keywords: colon adenocarcinoma, rectal adenocarcinoma, neuroendocrine tumors,  pancreatic tumors, gastrointestinal stromal tumors

EDUCATION

PhD, Medicine, University of São Paulo

Postdoctoral Fellow, Hematology and Oncology, Texas University, MD Anderson Cancer Center

Full professor of Oncology, University of São Paulo

INVESTIGATION AREAS

Oncology

ADITIONAL INFORMATION

AWARDS AND HONORS

Fellow of the American Society of Clinical Oncology (2018)

Member of the National Academy of Medicine (2017)

Jabuti Award, Brazilian Association of Literature (2014)

First Brazilian to be elected for the directors' board of the American Society of Clinical Oncology (2013-2018)

MD Anderson Cancer Center Award - Professor of the year (2000)

Selected Publications

H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes,
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making, Annals of Oncology, Volume 23, Issue 10, 2012, Pages 2479-2516, ISSN 0923-7534.
doi: 10.1093/annonc/mds236

Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.
doi: 10.1200/JCO.2001.19.8.2282

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 1;24(13):2065-72. doi: 10.1200/JCO.2005.05.3074. PMID: 16648507
doi: 10.1093/jnci/djx253

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53. PMID: 16857785.
doi: 10.1158/1078-0432.CCR-06-0038

Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009 Sep 1;27(25):4103-8. Epub 2009 Jul 27. PMID: 19636014.
doi: 10.1200/JCO.2008.21.0807

More Content